Valuation

RVMDREVOLUTION Medicines Inc

StockNasdaqUnited StatesHealth careEU retail investors: available

−2.4% today · +167.9% over a year

1/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 20% of the instruments we score

Trend: among the best of its peers; Quality: among the weakest; priced higher than most peers. No dividend.

REVOLUTION Medicines Inc (RVMD) valuation against sector peers: P/B 15.9, free-cash-flow yield −3.8%, P/S 151.0.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricRVMDSector medianvs median
P/E—30.6 · n=159—
P/B15.93.9 · n=309305% above
P/S151.04.0 · n=3033,635% above
EV/EBIT—25.1 · n=147—
Free-cash-flow yield−3.8%1.4% · n=290377% below
Dividend yield0.00%0.00% · n=362—
Return on equity−93.6%−2.2% · n=311—
Return on invested capital−74.1%0.6% · n=28511,958% below
Gross margin—63.3% · n=205—
Net debt / EBITDA—1.27 · n=151—

Value factor: 18 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

LLYEli Lilly & Co48.733.3—1.5%0.7%6/10
JNJJohnson & Johnson42.48.4—3.0%1.9%8/10
ABBVAbbVie50.5—27.83.6%2.9%6/10
UNHUnitedHealth22.93.517.36.3%2.2%10/10
MRKMerck147.78.1—4.1%2.3%8/10
TMOThermo Fisher Scientific36.64.734.72.9%0.3%9/10
AMGNAmgen26.917.623.33.8%2.1%8/10
GILDGilead Sciences—16.0—6.6%1.9%5/10
ABTAbbott39.53.632.13.6%2.9%6/10
PFEPfizer40.71.8—7.2%7.5%1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 04 Nov 2026